Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of November 2020, with a specific reporting date of November 17, 2020. The document serves as a transaction notification regarding insider trading activities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the company. It exclusively details a specific securities transaction:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Price: $37.7500 per ADS.
- Total Volume: 1,978.745 ADSs (comprising 1,935.745 ADSs via the Executive Supplemental Savings Plan and 43 ADSs via the 401(k) plan).
- Transaction Date: November 12, 2020.
- Exchange: New York Stock Exchange (XNYS).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. The only change reported is the increase in share ownership by Dr. H. Barron due to dividend reinvestment.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions described are routine acquisitions of notional ADSs within Dr. Barron's retirement accounts following the reinvestment of dividends.
Key Facts for Investor Verification
- Dr. H. Barron, Chief Scientific Officer and President, R&D, acquired 1,978.745 ADSs on November 12, 2020.
- The acquisition was executed at a price of $37.7500 per share.
- The transactions were automatic dividend reinvestments within the GSK Executive Supplemental Savings Plan and the GSK 401(k) plan, not open-market purchases.
- This filing does not provide any new financial performance data for GSK Plc.